Welcome to Abattis Bioceuticals Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law's of Canada and Foreign Jurisdictions. For more information, visit the Company's website at:
3/12/2014 420 Investor & Abattis : http://www.marketfy.com/product/420investor/lessons/816/view/42483/
2/25/2014 VIDEO INTERVIEW : http://www.cannabisfn.com/mdc/abattis-bioceuticals-corp/
AUDIO INTERVIEW w/ Mike Withrow (CEO) 2/11/2014: http://marketradio.ca/audio/abattis.mp3
President and CEO Mike Withrow
T: (604) 538-6650
C: (778) 896-6536
Abattis Bioceuticals Corp. Partnership, Joint Venture and Acquisition Presentation:http://www.abattis.com/i/pdf/Abattis-June-2013.pdf
Abattis Bioceuticals Corp. Investor Summary: http://www.abattis.com/i/pdf/investor-summary-Aug-2013.pdf
$ATTBF - Abattis Share Structure
January 28, 2014-
As at the date of this MD&A, the Company has 32,084,094 common shares issued and outstanding,
2,675,000 share purchase options outstanding and 4,570,000 share purchase warrants outstanding.
On a fully diluted basis, 39,329,094 common shares were outstanding.
Febuary 3, 2014-
Michael Withrow (CEO)
Following the acquisition referred to in Item 2 above, the offeror owns, directly and indirectly 8,740,300 common shares in the capital of the Issuer representing approximately 26.0% of the Issuer’s issued common shares, and owns, directly and indirectly, warrants entitling the purchase of an aggregate 1,330,000 common shares of the Issuer and options entitling the purchase of an aggregate of 690,000 common shares, or, assuming exercise of these warrants and options by the offeror, he would own, directly and indirectly, a total of 10,760,300 common shares or approximately 32.0% of the Issuer’s issued and outstanding common shares on a partially diluted basis.
VIDEO ON CANADIAN BNN: http://www.dailymotion.com/video/x209a39_abattis-bioceuticals-on-bnn_news